CN119031916A - 包含sos1抑制剂和egfr抑制剂的组合疗法 - Google Patents

包含sos1抑制剂和egfr抑制剂的组合疗法 Download PDF

Info

Publication number
CN119031916A
CN119031916A CN202380032772.0A CN202380032772A CN119031916A CN 119031916 A CN119031916 A CN 119031916A CN 202380032772 A CN202380032772 A CN 202380032772A CN 119031916 A CN119031916 A CN 119031916A
Authority
CN
China
Prior art keywords
inhibitor
sos1
cancer
pharmaceutically acceptable
egfr inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032772.0A
Other languages
English (en)
Chinese (zh)
Inventor
雅各布·哈林
希尔皮·卡雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN119031916A publication Critical patent/CN119031916A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380032772.0A 2022-04-08 2023-03-13 包含sos1抑制剂和egfr抑制剂的组合疗法 Pending CN119031916A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329090P 2022-04-08 2022-04-08
US63/329,090 2022-04-08
PCT/US2023/015097 WO2023196086A2 (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Publications (1)

Publication Number Publication Date
CN119031916A true CN119031916A (zh) 2024-11-26

Family

ID=88243368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032772.0A Pending CN119031916A (zh) 2022-04-08 2023-03-13 包含sos1抑制剂和egfr抑制剂的组合疗法

Country Status (10)

Country Link
US (1) US20250177410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504171A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512999A (cg-RX-API-DMAC7.html)
KR (1) KR20240170920A (cg-RX-API-DMAC7.html)
CN (1) CN119031916A (cg-RX-API-DMAC7.html)
AU (1) AU2023250819A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245678A1 (cg-RX-API-DMAC7.html)
IL (1) IL315645A (cg-RX-API-DMAC7.html)
MX (1) MX2024012445A (cg-RX-API-DMAC7.html)
WO (1) WO2023196086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250059182A1 (en) * 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2025090808A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer
WO2025090810A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230101312A1 (en) 2020-02-24 2023-03-30 Mirati Therapeutics, Inc. Sos1 inhibitors
EP4188383A4 (en) 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
CA3196287A1 (en) * 2020-10-20 2022-04-28 Binhua Lv Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
CA3221608A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents

Also Published As

Publication number Publication date
MX2024012445A (es) 2024-11-08
CA3245678A1 (en) 2023-10-12
EP4504171A4 (en) 2026-03-18
JP2025512999A (ja) 2025-04-22
WO2023196086A3 (en) 2023-12-07
KR20240170920A (ko) 2024-12-05
IL315645A (en) 2024-11-01
EP4504171A2 (en) 2025-02-12
WO2023196086A2 (en) 2023-10-12
US20250177410A1 (en) 2025-06-05
AU2023250819A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
CN112955137B (zh) 组合疗法
JP2024537140A (ja) Kras g12d阻害剤とsos1阻害剤との併用療法
JP2022500381A (ja) 組み合わせ療法
JP2024537136A (ja) KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法
JP2022500384A (ja) 組み合わせ療法
JP2022500385A (ja) 組み合わせ療法
JP2024540839A (ja) Kras g12d阻害剤とshp-2阻害剤との併用療法
JP2022500388A (ja) 組み合わせ療法
JP2024537139A (ja) KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法
JP2024521788A (ja) 併用療法
JP2025512999A (ja) Sos1阻害剤及びegfr阻害剤を含む併用療法
JP2024537137A (ja) Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法
US20250186453A1 (en) Combination therapies comprising a sos1 inhibitor and a mek inhibitor
HK40101229A (zh) 组合疗法
CN117615762A (zh) 组合疗法
HK40109894A (en) Combination therapies of kras g12d inhibitors with pan erbb family inhibitors
HK40109896A (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
HK40108895A (en) Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
HK40109895A (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
TW202428280A (zh) 組合療法
HK40055040A (en) Combination therapies
TW202517275A (zh) 藥物組合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination